Hydroxychloroquine sulfate Solid powder Inhibitors Hydroxychloroquine sulfate is an autophagy inhibitor. It acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR9. 433.94
$ $99 In stock
Formulation: 433.94
Source:
Usage:
Hydroxychloroquine sulfate - 747-36-4 (sulfate)

Hydroxychloroquine sulfate

The product is for non-human research only. Not for therapeutic or veterinary use.

Catalog No: bt-271274

CAS No: 747-36-4 (sulfate)

Molecular Formula: C18H28ClN3O5S

Molecular Weight: 433.94

CAS Number 747-36-4 (sulfate)
Product Name Hydroxychloroquine sulfate
Appearance Solid powder
Description Hydroxychloroquine sulfate is an autophagy inhibitor. It acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR9.
IUPAC Name 2-((4-((7-chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethan-1-ol sulfate
Molecular Formula C18H28ClN3O5S
Molecular Weight 433.94
Purity >98% (or refer to the Certificate of Analysis)
Shelf Life >3 years if stored properly
SMILES CCN(CCO)CCCC(NC1=CC=NC2=CC(Cl)=CC=C12)C.O=S(O)(O)=O
Solubility Soluble in DMSO
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Synonyms Hydroxychloroquine sulfate;
Reference 1: Haładyj E, Sikora M, Felis-Giemza A, Olesińska M. Antimalarials - are they effective and safe in rheumatic diseases? Reumatologia. 2018;56(3):164-173. doi: 10.5114/reum.2018.76904. Epub 2018 Jun 30. Review. PubMed PMID: 30042604; PubMed Central PMCID: PMC6052376. 2: Bigelsen S. Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin. Cancer Manag Res. 2018 Jul 13;10:2003-2018. doi: 10.2147/CMAR.S161824. eCollection 2018. Review. PubMed PMID: 30034255; PubMed Central PMCID: PMC6049054. 3: Betancourt BY, Biehl A, Katz JD, Subedi A. Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors. Rheum Dis Clin North Am. 2018 Aug;44(3):371-391. doi: 10.1016/j.rdc.2018.03.010. Epub 2018 Jun 12. Review. PubMed PMID: 30001781; PubMed Central PMCID: PMC6047536. 4: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501150/ PubMed PMID: 30000209. 5: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501146/ PubMed PMID: 30000205. 6: Klay D, Hoffman TW, Harmsze AM, Grutters JC, van Moorsel CHM. Systematic review of drug effects in humans and models with surfactant-processing disease. Eur Respir Rev. 2018 Jul 11;27(149). pii: 170135. doi: 10.1183/16000617.0135-2017. Print 2018 Sep 30. Review. PubMed PMID: 29997245. 7: Tekin ZE, Yener GO, Yüksel S. Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. Rheumatol Int. 2018 Aug;38(8):1577-1584. doi: 10.1007/s00296-018-4088-z. Epub 2018 Jun 27. Review. PubMed PMID: 29951963. 8: Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, Berrino L. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology. 2018 Jun 9. doi: 10.1007/s10787-018-0498-5. [Epub ahead of print] Review. PubMed PMID: 29948492. 9: Yusuf IH, Foot B, Galloway J, Ardern-Jones MR, Watson SL, Yelf C, Burdon MA, Bishop PN, Lotery AJ. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye (Lond). 2018 Jun 11. doi: 10.1038/s41433-018-0136-x. [Epub ahead of print] Review. PubMed PMID: 29887605; PubMed Central PMCID: PMC6043500. 10: Tenti S, Fabbroni M, Mancini V, Russo F, Galeazzi M, Fioravanti A. Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: A case report and review of the literature. Autoimmun Rev. 2018 Aug;17(8):791-795. doi: 10.1016/j.autrev.2018.02.010. Epub 2018 Jun 6. Review. PubMed PMID: 29885539. 11: Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: An old drug with new relevance. Cleve Clin J Med. 2018 Jun;85(6):459-467. doi: 10.3949/ccjm.85a.17034. Review. PubMed PMID: 29883308. 12: Sontheimer RD. Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity? Ann Transl Med. 2018 Apr;6(8):154. doi: 10.21037/atm.2018.03.05. Review. PubMed PMID: 29862243; PubMed Central PMCID: PMC5952016. 13: Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf. 2018 Jun 1. doi: 10.1007/s40264-018-0689-4. [Epub ahead of print] Review. PubMed PMID: 29858838. 14: Chighizola CB, Meroni PL. Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. Curr Rheumatol Rep. 2018 May 31;20(7):44. doi: 10.1007/s11926-018-0741-5. Review. PubMed PMID: 29850957. 15: Mohammadpour F, Kargar M, Hadjibabaie M. The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature. J Res Pharm Pract. 2018 Jan-Mar;7(1):4-12. doi: 10.4103/jrpp.JRPP_17_60. Review. PubMed PMID: 29755993; PubMed Central PMCID: PMC5934986. 16: Plantone D, Koudriavtseva T. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. Clin Drug Investig. 2018 May 8. doi: 10.1007/s40261-018-0656-y. [Epub ahead of print] Review. PubMed PMID: 29737455. 17: Casian A, Sangle SR, D'Cruz DP. New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis. Autoimmun Rev. 2018 Jul;17(7):660-664. doi: 10.1016/j.autrev.2018.01.016. Epub 2018 May 2. Review. PubMed PMID: 29729450. 18: Signorelli F, Balbi GGM, Domingues V, Levy RA. New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. Pharmacol Res. 2018 Jul;133:108-120. doi: 10.1016/j.phrs.2018.04.012. Epub 2018 Apr 30. Review. PubMed PMID: 29715499. 19: Onorati AV, Dyczynski M, Ojha R, Amaravadi RK. Targeting autophagy in cancer. Cancer. 2018 Apr 19. doi: 10.1002/cncr.31335. [Epub ahead of print] Review. PubMed PMID: 29671878. 20: Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cauli A. Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Mediators Inflamm. 2018 Feb 18;2018:3424136. doi: 10.1155/2018/3424136. eCollection 2018. Review. PubMed PMID: 29670462; PubMed Central PMCID: PMC5835241.